findmyKOL
Clinical trialNCT04934670TerminatedPhase 3Interventional

A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)

SponsorXenikosEnrollment12Steroid-Refractory Acute Graft Versus Host Disease
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open-label, randomized, Phase 3, multicenter trial, which has been designed to compare the efficacy and safety of T-Guard to ruxolitinib in patients with Grade III or IV Steroid-Refractory acute Graft-Versus-Host Disease (SR-aGVHD). The primary hypothesis is that T-Guard treatment will improve the Day 28 complete response (CR) rate in patients with Grades III and IV SR-aGVHD compared to ruxolitinib.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

48 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium
  • Site Be300

    Brussels, Belgium

  • Site Be301

    Brussels, Belgium

  • Site Be307

    Ghent, Belgium

  • Site Be305

    Leuven, Belgium

  • Site Be302

    Liège, Belgium

  • Site Be303

    Yvoir, Belgium

Croatia
  • Site Hr320

    Zagreb, Croatia

France
  • Site Fr341

    Angers, France

  • Site Fr345

    Créteil, France

  • Site Fr346

    La Tronche, France

  • Site Fr355

    Lille, France

  • Sitefr354

    Nantes, France

  • Sitefr342

    Paris, France

  • Sitefr348

    Paris, France

  • Site Fr356

    Pierre-Bénite, France

  • Site Fr351

    Saint-Priest-en-Jarez, France

  • Site Fr352

    Toulouse, France

Germany
  • Site De367

    Dresden, Germany

  • Site De364

    Essen, Germany

  • Site De371

    Hanover, Germany

  • Site De368

    Heidelberg, Germany

  • Site De360

    Leipzig, Germany

  • Site De362

    Mainz, Germany

  • Site De361

    Münster, Germany

Italy
  • Site It384

    Milan, Italy

Netherlands
  • Site Nl461

    Groningen, Netherlands

  • Site Nl460

    Maastricht, Netherlands

  • Site Nl463

    Nijmegen, Netherlands

Spain
  • Site Es447

    Barcelona, Spain

  • Site Es446

    Madrid, Spain

  • Site Es442

    Salamanca, Spain

  • Site Es451

    Santander, Spain

  • Site Es452

    Seville, Spain

  • Site Es453

    Valencia, Spain

  • Site Es454

    Valencia, Spain

United Kingdom
  • Site Gb483

    Cardiff, United Kingdom

United States
  • University of Alabama

    Birmingham, Alabama, United States

  • City of Hope National Medical Center

    Duarte, California, United States

  • H. Lee Moffitt Cancer Center

    Tampa, Florida, United States

  • Washington University St. Louis

    St Louis, Missouri, United States

8 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ruxolitinib →T-Guard
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
16 Jun 2022
Primary completion
10 Nov 2022
Completion
19 Jan 2023
Last update posted
27 Aug 2024
Registered enrollment
12
Registry id
NCT04934670

Cross-registrations

EU-CTR / CTIS (EudraCT)2021-000343-53
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.